AU714980B2 - Isobutylgaba and its derivatives for the treatment of pain - Google Patents

Isobutylgaba and its derivatives for the treatment of pain Download PDF

Info

Publication number: AU714980B2
Authority: AU; Australia
Prior art keywords: pain; treated; use according; hydrogen; methyl
Prior art date: 1996-07-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

AU36024/97A

Other languages

English (en)

Other versions

AU3602497A (en

Inventor

Lakhbir Singh

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Warner Lambert Co LLC

Original Assignee

Warner Lambert Co LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-24

Filing date

1997-07-16

Publication date

2000-01-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21809080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU714980(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-07-16 Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC

1998-02-10 Publication of AU3602497A publication Critical patent/AU3602497A/en

2000-01-13 Application granted granted Critical

2000-01-13 Publication of AU714980B2 publication Critical patent/AU714980B2/en

2013-05-16 Assigned to WARNER-LAMBERT COMPANY LLC reassignment WARNER-LAMBERT COMPANY LLC Request to Amend Deed and Register Assignors: WARNER-LAMBERT COMPANY

2017-07-16 Anticipated expiration legal-status Critical

Status Expired legal-status Critical Current

Links

208000002193 Pain Diseases 0.000 title claims abstract description 64
238000011282 treatment Methods 0.000 title claims description 12
238000000034 method Methods 0.000 claims abstract description 30
150000001875 compounds Chemical class 0.000 claims description 32
229910052739 hydrogen Inorganic materials 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 13
125000004432 carbon atom Chemical group C* 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
208000004550 Postoperative Pain Diseases 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
150000002431 hydrogen Chemical class 0.000 claims description 7
AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 6
208000004296 neuralgia Diseases 0.000 claims description 6
208000021722 neuropathic pain Diseases 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
206010065390 Inflammatory pain Diseases 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
208000001387 Causalgia Diseases 0.000 claims description 4
208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 4
206010058019 Cancer Pain Diseases 0.000 claims description 3
201000005569 Gout Diseases 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
MHPUGCYGQWGLJL-UHFFFAOYSA-N 5-methyl-hexanoic acid Chemical compound CC(C)CCCC(O)=O MHPUGCYGQWGLJL-UHFFFAOYSA-N 0.000 claims 2
230000003349 osteoarthritic effect Effects 0.000 claims 2
230000000052 comparative effect Effects 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000003643 water by type Substances 0.000 claims 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 6
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract description 3
229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 3
238000002560 therapeutic procedure Methods 0.000 abstract description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 2
235000013922 glutamic acid Nutrition 0.000 abstract description 2
239000004220 glutamic acid Substances 0.000 abstract description 2
208000004454 Hyperalgesia Diseases 0.000 description 62
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 58
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 35
210000002683 foot Anatomy 0.000 description 32
229960002870 gabapentin Drugs 0.000 description 28
241001465754 Metazoa Species 0.000 description 27
238000001356 surgical procedure Methods 0.000 description 20
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
241000700159 Rattus Species 0.000 description 18
229960005181 morphine Drugs 0.000 description 17
230000000694 effects Effects 0.000 description 15
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 13
230000004044 response Effects 0.000 description 13
238000012360 testing method Methods 0.000 description 13
230000003447 ipsilateral effect Effects 0.000 description 11
239000003981 vehicle Substances 0.000 description 11
229920001525 carrageenan Polymers 0.000 description 9
235000010418 carrageenan Nutrition 0.000 description 9
229940079593 drug Drugs 0.000 description 9
238000007920 subcutaneous administration Methods 0.000 description 9
208000035154 Hyperesthesia Diseases 0.000 description 8
238000000692 Student's t-test Methods 0.000 description 8
238000011161 development Methods 0.000 description 8
210000000548 hind-foot Anatomy 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
230000003040 nociceptive effect Effects 0.000 description 8
238000012353 t test Methods 0.000 description 8
210000004209 hair Anatomy 0.000 description 7
238000000540 analysis of variance Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
230000006698 induction Effects 0.000 description 5
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
206010053552 allodynia Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
244000144993 groups of animals Species 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000002027 skeletal muscle Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
208000028389 Nerve injury Diseases 0.000 description 2
229920005439 Perspex® Polymers 0.000 description 2
208000004983 Phantom Limb Diseases 0.000 description 2
206010056238 Phantom pain Diseases 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
-1 aliphatic nitro compounds Chemical class 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000003070 anti-hyperalgesia Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
210000003195 fascia Anatomy 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
208000014674 injury Diseases 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000008764 nerve damage Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
208000000412 Avitaminosis Diseases 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
238000006845 Michael addition reaction Methods 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
206010068106 Occipital neuralgia Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010047627 Vitamin deficiencies Diseases 0.000 description 1
KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003574 anti-allodynic effect Effects 0.000 description 1
230000000573 anti-seizure effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
108010056028 auromycin Proteins 0.000 description 1
239000002585 base Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000003461 brachial plexus Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
MNBODUCODDEXEE-UHFFFAOYSA-N ethyl 4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C MNBODUCODDEXEE-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000000917 hyperalgesic effect Effects 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000011542 limb amputation Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
OBLVSONFNRLRIQ-UHFFFAOYSA-N lithium;ethyl acetate Chemical compound [Li+].CCOC([CH2-])=O OBLVSONFNRLRIQ-UHFFFAOYSA-N 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
201000005518 mononeuropathy Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
210000001032 spinal nerve Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229940063650 terramycin Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
238000009901 transfer hydrogenation reaction Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
208000009852 uremia Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AU36024/97A 1996-07-24 1997-07-16 Isobutylgaba and its derivatives for the treatment of pain Expired AU714980B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2233796P	1996-07-24	1996-07-24
US60/022337		1996-07-24
PCT/US1997/012390 WO1998003167A1 (en)	1996-07-24	1997-07-16	Isobutylgaba and its derivatives for the treatment of pain

Publications (2)

Publication Number	Publication Date
AU3602497A AU3602497A (en)	1998-02-10
AU714980B2 true AU714980B2 (en)	2000-01-13

Family

ID=21809080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU36024/97A Expired AU714980B2 (en)	1996-07-24	1997-07-16	Isobutylgaba and its derivatives for the treatment of pain

Country Status (23)

Country	Link
US (2)	USRE41920E1 (2)
EP (1)	EP0934061B3 (2)
JP (1)	JP3693258B2 (2)
KR (1)	KR100491282B1 (2)
CN (1)	CN1094757C (2)
AT (1)	ATE241351T1 (2)
AU (1)	AU714980B2 (2)
BR (1)	BR9710536A (2)
CA (1)	CA2255652C (2)
CU (1)	CU22850A3 (2)
DE (1)	DE69722426T3 (2)
DK (1)	DK0934061T6 (2)
ES (1)	ES2200184T7 (2)
HR (1)	HRP970387A2 (2)
HU (2)	HU228426B1 (2)
IL (1)	IL126999A (2)
NO (2)	NO325822B1 (2)
NZ (1)	NZ332762A (2)
PL (1)	PL189872B1 (2)
PT (1)	PT934061E (2)
SI (1)	SI0934061T1 (2)
WO (1)	WO1998003167A1 (2)
ZA (1)	ZA976562B (2)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP980342A2 (en) *	1997-06-25	1999-02-28	Warner Lambert Co	Anti-inflammatory method
US6329429B1 (en)	1997-06-25	2001-12-11	Warner-Lambert Company	Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
WO1999012537A1 (en) *	1997-09-08	1999-03-18	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same
EP0974351A3 (en) *	1998-04-24	2000-12-13	Jouveinal	Medicament for preventing and treating gastrointestinal damage
ATE271864T1 (de) *	1998-05-15	2004-08-15	Warner Lambert Co	Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
AU766708B2 (en) *	1998-07-09	2003-10-23	Warner-Lambert Company	The treatment of renal colic with GABA analogs
EP1093366B1 (en) *	1998-07-09	2004-10-13	Warner-Lambert Company LLC	Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles
US20030045500A1 (en) *	1998-07-09	2003-03-06	Leslie Magnus	Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
KR20010074682A (ko) *	1998-07-09	2001-08-09	로즈 암스트롱, 크리스틴 에이. 트러트웨인	부비동 두통을 완화시키기 위한 ｇａｂａ 유사체 및충혈제거제를 포함하는 조성물
US6680343B1 (en)	1998-07-09	2004-01-20	Warner-Lambert Comapny	Treatment of renal colic with GABA analogs
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
WO2000067742A2 (en) *	1999-05-05	2000-11-16	Warner-Lambert Company	Use of gaba analogues for the modulation of substance p
US20080207755A1 (en) *	2000-05-31	2008-08-28	Pfizer Inc	Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
ES2317839T3 (es) *	1999-06-10	2009-05-01	Warner-Lambert Company Llc	Acidos 3-propil gamma-aminobutiricos monosustituidos.
US7164034B2 (en) *	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
EP1840117A1 (en) *	1999-06-10	2007-10-03	Warner-Lambert Company LLC	Mono- and disubstituted 3-propyl gamma-aminobutyric acids
IL139073A0 (en) *	1999-10-21	2001-11-25	Pfizer	Treatment of neuropathy
PT1250311E (pt) *	2000-01-27	2004-07-30	Warner Lambert Co	Sintese assimetrica de pregabalina
US6687187B2 (en) *	2000-08-11	2004-02-03	Phonak Ag	Method for directional location and locating system
CA2356829A1 (en) *	2000-09-22	2002-03-22	Warner-Lambert Company	Method for treating asthma using pregabalin
US6620829B2 (en) *	2000-10-17	2003-09-16	Warner-Lambert Company	Method of treating noninflammatory cartilage damage
GB2368579A (en) *	2000-10-31	2002-05-08	Parke Davis & Co Ltd	Azole pharmaceutical agents
DE60120104T2 (de) *	2001-03-20	2006-09-21	Schwarz Pharma Ag	Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) *	2001-03-21	2003-03-17	Sanol Arznei Schwarz Gmbh	Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
US7186855B2 (en) *	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) *	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE540678T1 (de) *	2001-06-11	2012-01-15	Xenoport Inc	Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) *	2001-06-11	2008-09-02	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
IL160523A0 (en)	2001-09-03	2004-07-25	Newron Pharm Spa	PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
WO2003077902A1 (en) *	2002-02-19	2003-09-25	Xenoport, Inc.	Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003099338A2 (en) *	2002-05-17	2003-12-04	Xenoport, Inc.	Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0219024D0 (en) *	2002-08-15	2002-09-25	Pfizer Ltd	Synergistic combinations
US7273889B2 (en) *	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004053192A1 (en) *	2002-12-11	2004-06-24	Xenoport, Inc.	Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
WO2004052360A1 (en) *	2002-12-11	2004-06-24	Xenoport, Inc.	Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
PL377286A1 (pl) *	2002-12-13	2006-01-23	Warner-Lambert Company Llc	Analogi gabapentyny do włókniako-mięśniakowych i innych pokrewnych zaburzeń
BR0317253A (pt) *	2002-12-13	2005-11-01	Warner Lambert Co	Derivados pregabalina para o tratamento da fibromialgia e outras patologias
WO2004054560A1 (en)	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
MXPA05006209A (es) *	2002-12-13	2005-08-19	Warner Lambert Co	Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
CA2451267A1 (en)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
US20080318908A1 (en) *	2002-12-17	2008-12-25	Trustees Of Tufts College	Use of gaba and gabab agonists
NZ545494A (en) *	2003-09-12	2009-10-30	Pfizer	Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
AU2004274002B2 (en) *	2003-09-17	2011-04-28	Arbor Pharmaceuticals, Llc	Treating or preventing restless legs syndrome using prodrugs of GABA analogs
PT1677767E (pt) *	2003-10-14	2011-10-13	Xenoport Inc	Forma cristalina de análogo de ácido gama-aminobutírico
JP4664924B2 (ja) *	2003-12-02	2011-04-06	ウーツェーベーファルマゲーエムベーハー	中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
RU2335342C2 (ru) *	2004-03-12	2008-10-10	Уорнер-Ламберт Компани Ллс	C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина
US20100256179A1 (en) *	2004-03-26	2010-10-07	Ucb Pharma Gmbh	Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) *	2004-03-26	2007-02-22	Srz Properties, Inc.	Combination therapy for pain in painful diabetic neuropathy
EP1735324B1 (en) *	2004-04-01	2008-08-20	Warner-Lambert Company LLC	Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
AU2005232395B2 (en)	2004-04-16	2010-09-09	Schwarz Pharma Ag	Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) *	2004-06-09	2005-12-14	Schwarz Pharma Ag	Novel use of peptide compounds for treating pain in trigeminal neuralgia
MXPA06014228A (es) *	2004-06-21	2007-02-14	Warner Lambert Co	Preparacion de pregabalina y compuestos relacionados.
EA014055B1 (ru) *	2004-08-27	2010-08-30	Шварц Фарма Аг	Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
CA2584338C (en)	2004-11-04	2013-08-06	Xenoport, Inc.	Gabapentin prodrug sustained release oral dosage forms
US20070043241A1 (en) *	2005-05-10	2007-02-22	Lilach Hedvati	Optical resolution of 3-carbamoylmethyl-5-methylhexanoic acid
ATE486841T1 (de) *	2005-05-10	2010-11-15	Teva Pharma	Verfahren zur herstellung von pregabalin und salzen daraus
WO2006124609A2 (en) *	2005-05-16	2006-11-23	Joseph Johnson	Methods and compositions for treating arg
AU2006248645A1 (en) *	2005-05-20	2006-11-23	Pfizer Limited	Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
EP1754476A1 (en) *	2005-08-18	2007-02-21	Schwarz Pharma Ag	Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) *	2005-08-18	2007-02-22	Bettina Beyreuther	Therapeutic combination for painful medical conditions
US20070048372A1 (en) *	2005-08-18	2007-03-01	Srz Properties, Inc.	Method for treating non-inflammatory osteoarthritic pain
KR20070087596A (ko)	2005-09-19	2007-08-28	테바 파마슈티컬 인더스트리즈 리미티드	(ｓ)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성
US7462738B2 (en) *	2006-05-24	2008-12-09	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
EA019757B1 (ru)	2006-06-15	2014-06-30	ЮСиБи ФАРМА ГМБХ	Фармацевтическая композиция с синергетическим противосудорожным эффектом
MX2008014759A (es) *	2007-03-22	2009-03-09	Teva Pharma	Sintesis del acido (s)-(+)-3-(aminometil)-5-metil hexanoico.
KR20090101462A (ko) *	2007-10-03	2009-09-28	테바 파마슈티컬 인더스트리즈 리미티드	프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
US20100087525A1 (en) *	2008-06-23	2010-04-08	Lilach Hedvati	Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010070593A2 (en)	2008-12-19	2010-06-24	Pfizer Ireland Pharmaceuticals	Malonate esters
US9192681B2 (en)	2009-02-24	2015-11-24	Nektar Therapeutics	Oligomer-amino acid conjugates
EA201101564A1 (ru) *	2009-05-15	2012-07-30	Редкс Фарма Лимитед	Редокс производные лекарственных средств
WO2010150221A1 (en)	2009-06-25	2010-12-29	Wockhardt Research Centre	Taste masked pharmaceutical compositions of pregabalin
US20110124705A1 (en) *	2009-11-24	2011-05-26	Xenoport, Inc.	Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110130454A1 (en) *	2009-11-24	2011-06-02	Xenoport, Inc.	Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
EP2509596B1 (en)	2009-12-08	2019-08-28	Case Western Reserve University	Gamma aminoacids for treating ocular disorders
HU230031B1 (hu)	2010-03-01	2015-05-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
WO2011141923A2 (en)	2010-05-14	2011-11-17	Lupin Limited	Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
US20130078290A1 (en)	2010-06-01	2013-03-28	Rubicon Research Private Limited	Gastroretentive Dosage Forms Of GABA Analogs
WO2012025861A1 (en)	2010-08-23	2012-03-01	Pfizer Manufacturing Ireland	Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin
US8466297B2 (en)	2010-11-01	2013-06-18	Milan Soukup	Manufacturing process for (S)-Pregabalin
WO2012059797A1 (en)	2010-11-04	2012-05-10	Lupin Limited	Process for synthesis of (s) - pregabalin
AU2013213769A1 (en)	2012-01-30	2014-08-21	Sun Pharmaceutical Industries Limited	Gastroretentive tablets
US20140378545A1 (en)	2012-01-30	2014-12-25	Ranbaxy Laboratories Limited	Pregabalin gr tablets
CN102966602B (zh) *	2012-12-14	2015-08-05	江苏海鸥冷却塔股份有限公司	一种冷却塔节能导流风筒
WO2014112152A1 (ja)	2013-01-18	2014-07-24	有限会社ケムフィズ	神経因性疾病の治療のための医薬
PL2978748T3 (pl)	2013-03-27	2017-09-29	Pfizer Ireland Pharmaceuticals	Sposób i związki pośrednie do wytwarzania pregabaliny
JP2018520112A (ja)	2015-05-26	2018-07-26	オディディ，イサ	制御持続放出プレガバリン
GB201617380D0 (en) *	2016-10-13	2016-11-30	St George's Hospital Medical School	Treatment for Osteoarthritis
KR102039345B1 (ko)	2017-02-01	2019-11-01	지엘팜텍주식회사	프레가발린 함유 고팽윤성 서방성 삼중정제
KR102039344B1 (ko)	2017-02-01	2019-11-01	지엘팜텍주식회사	프레가발린 함유 경구용 서방성 삼중정제
GB201703123D0 (en) *	2017-02-27	2017-04-12	St George's Hospital Medical School	Biomarkers
CN112424158A (zh)	2018-05-14	2021-02-26	昌郁医药公司	萘普生和普瑞巴林的1-(酰氧基)-烷基氨基甲酸酯药物缀合物的结晶形式
CN108926573A (zh) *	2018-07-03	2018-12-04	泓博元生命科技（深圳）有限公司	一种可降低尿酸指数的nadh组合物及其制备方法及应用
KR20200056719A (ko)	2018-11-15	2020-05-25	단국대학교 천안캠퍼스 산학협력단	가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물
PH12022551856A1 (en)	2020-01-22	2024-01-03	Seelos Therapeutics Inc	Reducing side effects of nmda antagonists
WO2021191108A1 (en)	2020-03-23	2021-09-30	Plus Vitech, S.L.	Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid
WO2022038131A1 (en)	2020-08-19	2022-02-24	Plus Vitech, S.L.	Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage
AU2022210856A1 (en)	2021-01-22	2023-08-17	Egis Gyógyszergyár Zrt.	Topical formulation containing modified phospholipid compounds
HU231397B1 (hu)	2021-01-22	2023-06-28	Egis Gyógyszergyár Zrt.	Pregabalint tartalmazó topikális gyógyszerkészítmény
WO2022234110A1 (en)	2021-05-07	2022-11-10	Plus Vitech, S.L.	Gamma-aminobutyric acid derivatives for use in cancer therapy
WO2022243430A1 (en)	2021-05-20	2022-11-24	Plus Vitech, S.L.	Treatment of acne
WO2022253748A1 (en)	2021-06-03	2022-12-08	Plus Vitech, S.L.	Combinations for the treatment of hpv

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH449645A (de)	1963-07-09	1968-01-15	Ciba Geigy	Verfahren zur Herstellung neuer Aminosäuren
JPS4940460Y2 (2)	1971-05-19	1974-11-06
DE2460891C2 (de)	1974-12-21	1982-09-23	Gödecke AG, 1000 Berlin	1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en)	1974-12-21	1978-05-02	Warner-Lambert Company	Treatment of cranial dysfunctions using novel cyclic amino acids
US4123438A (en)	1975-03-05	1978-10-31	Stamicarbon, B.V.	Process for preparing 2-pyrrolidones
NZ194348A (en)	1979-07-26	1982-09-14	Merrell Toraude & Co	Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions
US4322440A (en)	1980-06-25	1982-03-30	New York University	Anticonvulsive compositions and method of treating convulsive disorders
US4513135A (en)	1982-03-05	1985-04-23	Eli Lilly And Company	Diaryl-pyrazine derivatives affecting GABA binding
DK373383A (da)	1982-08-20	1984-02-21	Midit	Fremgangsmaade til fremstilling af omega-aminosyrederivater
US4479005A (en)	1982-12-16	1984-10-23	The Dow Chemical Company	Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
DE133795T1 (de)	1983-08-01	1985-09-12	The Mclean Hospital Corp., Belmont, Mass.	Gaba-ester und gaba-analoge ester.
US5051448A (en)	1984-07-24	1991-09-24	The Mclean Hospital Corporation	GABA esters and GABA analog esters
GB8425872D0 (en)	1984-10-12	1984-11-21	Ciba Geigy Ag	Chemical compounds
NO166131C (no)	1985-06-20	1991-06-05	Daiichi Seiyaku Co	Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
US4956388A (en)	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
JP2535001B2 (ja)	1987-01-13	1996-09-18	ダイセル化学工業株式会社	Ｎ−アルキル化アミノ酸エステルの製法
JPH07116064B2 (ja)	1987-07-21	1995-12-13	三菱化学株式会社	分離剤
US4908210A (en)	1988-10-28	1990-03-13	Eastman Kodak Company	Lactylic salt tablet formulations and tablets
GB8911017D0 (en)	1989-05-13	1989-06-28	Ciba Geigy Ag	Substituted aminoalkylphosphinic acids
DE3928183A1 (de)	1989-08-25	1991-02-28	Goedecke Ag	Lactamfreie cyclische aminosaeuren
GB8921304D0 (en)	1989-09-20	1989-11-08	Wyeth John & Brother Ltd	New method of treatment and heterocyclic compounds used therein
US5104869A (en)	1989-10-11	1992-04-14	American Cyanamid Company	Renin inhibitors
US5084479A (en)	1990-01-02	1992-01-28	Warner-Lambert Company	Novel methods for treating neurodegenerative diseases
US5025035A (en)	1990-10-12	1991-06-18	Warner-Lambert Company	Method of treating depression
US6197819B1 (en)	1990-11-27	2001-03-06	Northwestern University	Gamma amino butyric acid analogs and optical isomers
AU9137091A (en) *	1990-11-27	1992-06-25	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
WO1992014443A1 (en)	1991-02-20	1992-09-03	Warner-Lambert Company	Microsphere-in-oil emulsion
DK204791D0 (da)	1991-12-20	1991-12-20	Novo Nordisk As	Hidtil ukendt farmaceutisk praeparat
JP3856816B2 (ja)	1992-05-20	2006-12-13	ノースウェスターンユニヴァーシティ	抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体
GB9308430D0 (en)	1993-04-23	1993-06-09	Glaxo Group Ltd	Medicaments
US5492927A (en)	1993-12-21	1996-02-20	Eli Lilly And Company	Non-peptide tachykinin receptor antagonists to treat allergy
US5652216A (en)	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
RU2168982C2 (ru)	1994-07-27	2001-06-20	Варнер-Ламберт Компани	Способ лечения состояния страха или лечения и/или предупреждения состояния паники, очищенный белок, способный связывать габапентин, и фармацевтическая композиция, обладающая успокоительным, противопаническим и противосудорожным действием
US5792796A (en)	1994-07-27	1998-08-11	Warner-Lambert Company	Methods for treating anxiety and panic
GB9420784D0 (en)	1994-10-14	1994-11-30	Glaxo Group Ltd	Medicaments
US5767117A (en)	1994-11-18	1998-06-16	The General Hospital Corporation	Method for treating vascular headaches
ES2229259T3 (es)	1995-01-12	2005-04-16	Glaxo Group Limited	Derivados de piperidina con actividad antagonista de taquiquinina.
RO119545B1 (ro)	1995-02-28	2004-12-30	H. Lundbeck A/S	Derivaţi de 4-aminotetrahidrobenzizoxazol ca inhibitori ai absorbţiei gaba
US5510381A (en)	1995-05-15	1996-04-23	Warner-Lambert Company	Method of treatment of mania and bipolar disorder
US5616793A (en)	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en)	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
EP0888325B1 (en)	1996-02-07	2002-05-29	Warner-Lambert Company	Novel cyclic amino acids as pharmaceutical agents
HU224720B1 (en)	1996-03-14	2006-01-30	Warner Lambert Co	Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
WO1997033859A1 (en)	1996-03-14	1997-09-18	Warner-Lambert Company	Novel bridged cyclic amino acids as pharmaceutical agents
US20020077461A1 (en)	1996-04-24	2002-06-20	Soren Bjorn	Pharmaceutical formulation
US6372792B1 (en)	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
WO1997049393A1 (en)	1996-06-26	1997-12-31	Warner-Lambert Company	Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
SE9603408D0 (sv)	1996-09-18	1996-09-18	Astra Ab	Medical use
HRP980342A2 (en)	1997-06-25	1999-02-28	Warner Lambert Co	Anti-inflammatory method
US6329429B1 (en)	1997-06-25	2001-12-11	Warner-Lambert Company	Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
AU9019198A (en)	1997-08-19	1999-03-08	Warner-Lambert Company	Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants
US6127418A (en)	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage
WO1999008670A1 (en)	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
WO1999012537A1 (en)	1997-09-08	1999-03-18	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same
SI1045839T1 (en)	1997-12-16	2004-06-30	Warner-Lambert Company Llc	Novel amines as pharmaceutical agents
ATE271864T1 (de)	1998-05-15	2004-08-15	Warner Lambert Co	Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
ID26395A (id)	1998-05-15	2000-12-21	Warner Lambert Comapny	Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
US6680343B1 (en)	1998-07-09	2004-01-20	Warner-Lambert Comapny	Treatment of renal colic with GABA analogs
WO2000002546A2 (en)	1998-07-09	2000-01-20	Warner-Lambert Company	Use of caba-analogues for treating insomnia
US20030045500A1 (en)	1998-07-09	2003-03-06	Leslie Magnus	Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles
EP1094817A1 (en)	1998-07-09	2001-05-02	Warner-Lambert Company	Compositions comprising gaba analogs and caffeine
CA2344407C (en)	1998-10-16	2007-01-09	Warner-Lambert Company	Method for the treatment of mania and bipolar disorder
US6451857B1 (en)	1999-03-10	2002-09-17	Warner-Lambert Company	Analgesic compositions comprising anti-epileptic compounds and methods of using same
US6992109B1 (en)	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
TR200102850T2 (tr)	1999-04-09	2002-03-21	Warner-Lambert Company	Depresyonun iyileçtirilmesi iin gaba analoglarì ve trisiklik bileçiklerin kombinasyonlarì
PT1187832E (pt)	1999-06-02	2003-03-31	Warner Lambert Co	Amino heterociclos uteis como agentes farmaceuticos
US6642398B2 (en)	1999-06-10	2003-11-04	Warner-Lambert Company	Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
WO2001001983A1 (en)	1999-07-02	2001-01-11	Warner-Lambert Company	A synergistic combination: gabapentin and pregabalin
US7030119B1 (en)	1999-07-16	2006-04-18	Warner-Lambert Company	Method for treating chronic pain using MEK inhibitors
JP2003512602A (ja)	1999-09-16	2003-04-02	ワーナー−ランバート・カンパニー	α２δ−１サブユニット結合リガンドのスクリーニング方法
AP2002002501A0 (en)	1999-10-07	2002-06-30	Warner Lambert Co	Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
PT1250311E (pt)	2000-01-27	2004-07-30	Warner Lambert Co	Sintese assimetrica de pregabalina
US20010036943A1 (en)	2000-04-07	2001-11-01	Coe Jotham W.	Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
JP2003533223A (ja)	2000-05-16	2003-11-11	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	α２δ２カルシウムチャネルサブユニットの発現細胞株
GB2365425A (en)	2000-08-01	2002-02-20	Parke Davis & Co Ltd	Alkyl amino acid derivatives useful as pharmaceutical agents
CA2356829A1 (en)	2000-09-22	2002-03-22	Warner-Lambert Company	Method for treating asthma using pregabalin
US6620829B2 (en)	2000-10-17	2003-09-16	Warner-Lambert Company	Method of treating noninflammatory cartilage damage
BR0115783A (pt)	2000-11-30	2003-09-16	Pfizer Prod Inc	Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase
EP1337272A2 (en)	2000-11-30	2003-08-27	Pfizer Products Inc.	Combination of gaba agonists and aldose reductase inhibitors
MXPA03004168A (es)	2000-12-13	2004-12-02	Warner Lambert Co	Sintesis de ligandos bisfosfolanos p-quirales y de sus complejos con metales de transicion para uso como catalizadores de hidrogenacion asimetrica.
US20040002543A1 (en)	2001-02-16	2004-01-01	Leslie Magnus	Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
EP1236720B1 (en)	2001-02-28	2005-06-15	Pfizer Products Inc.	Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
MXPA02001147A (es)	2001-03-19	2004-04-21	Warner Lambert Co	Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica.
US7022678B2 (en)	2001-03-30	2006-04-04	Warner-Lambert Company	Pregabalin lactose conjugates
EP1247809A3 (en)	2001-03-30	2003-12-17	Pfizer Products Inc.	Triazine compounds useful as sorbitol dehydrogenase inhibitors
CA2442476A1 (en)	2001-03-30	2002-10-10	Pfizer Products Inc.	Pyridazinone aldose reductase inhibitors
SK12822003A3 (sk)	2001-04-19	2004-04-06	Warner - Lambert Company Llc	Fúzne bicyklické alebo tricyklické aminokyseliny
SK286227B6 (sk)	2001-05-25	2008-05-06	Warner-Lambert Company Llc	Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie
US20030045449A1 (en)	2001-08-15	2003-03-06	Pfizer, Inc.	Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10203122A1 (de)	2002-01-25	2003-07-31	Gruenenthal Gmbh	Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
AU2003201716B2 (en)	2002-01-31	2008-04-17	Warner-Lambert Company Llc	Alpha 2 delta ligands to treat tinnitus
US6855724B2 (en)	2002-04-08	2005-02-15	Agouron Pharmaceuticals, Inc.	Tropane derivatives useful in therapy
US6713490B2 (en)	2002-04-26	2004-03-30	Pfizer, Inc.	3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
US20030225149A1 (en)	2002-04-30	2003-12-04	Blazecka Peter G.	Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
AU2003239752A1 (en)	2002-06-27	2004-01-19	Warner-Lambert Company Llc	Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
SI1521733T1 (sl)	2002-07-08	2014-10-30	Pfizer Products Inc.	Modulatorji glukokortikoidnega receptorja
US7053122B2 (en)	2002-08-09	2006-05-30	Pfizer Inc	Therapeutic use of aryl amino acid derivatives
US20040092522A1 (en)	2002-08-15	2004-05-13	Field Mark John	Synergistic combinations
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en)	2002-08-29	2006-07-04	Warner Lambert Company Llc	Process for preparing functionalized γ-butyrolactones from mucohalic acid
US7659305B2 (en)	2002-10-31	2010-02-09	Pfizer Inc.	Therapeutic proline derivatives
CA2508601A1 (en)	2002-12-06	2004-06-24	Warner-Lambert Company Llc	Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
CA2451267A1 (en)	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
MXPA05006209A (es)	2002-12-13	2005-08-19	Warner Lambert Co	Pregabalina y sus derivados para el tratamiento de fibromialgia y otros trastornos relacionados.
US7572910B2 (en)	2003-02-20	2009-08-11	Pfizer, Inc.	Pyridazinone aldose reductase inhibitors
WO2004100992A2 (en)	2003-05-16	2004-11-25	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1644360A1 (en)	2003-06-05	2006-04-12	Warner-Lambert Company LLC	3-substituted indoles and derivatives thereof as therapeutic agents
WO2005002585A1 (en)	2003-07-02	2005-01-13	Warner-Lambert Company Llc	Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
KR100738784B1 (ko)	2003-09-03	2007-07-12	화이자 인코포레이티드	5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
AU2004271796A1 (en)	2003-09-12	2005-03-24	Warner-Lambert Company Llc	Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
NZ545494A (en)	2003-09-12	2009-10-30	Pfizer	Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en)	2003-09-22	2003-10-22	Pfizer Ltd	Combinations
EP1670750A1 (en)	2003-09-25	2006-06-21	Warner-Lambert Company LLC	Prodrugs of amino acids with affinity for the alpha2delta- protein
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1543831A1 (en)	2003-12-18	2005-06-22	Pfizer GmbH Arzneimittelwerk Gödecke	Pregabalin composition
WO2005082372A1 (en)	2004-01-29	2005-09-09	Pfizer Products Inc.	COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
GB0405200D0 (en)	2004-03-08	2004-04-21	Pfizer Ltd	Combinations comprising alpha-2-delta ligands
RU2335342C2 (ru)	2004-03-12	2008-10-10	Уорнер-Ламберт Компани Ллс	C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина
CA2563164A1 (en)	2004-03-29	2005-10-06	Pfizer Inc.	Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
EP1735324B1 (en)	2004-04-01	2008-08-20	Warner-Lambert Company LLC	Preparation of p-chirogenic phospholanes and their use in asymetric synthesis
DE602005011784D1 (de)	2004-04-07	2009-01-29	Pfizer	Pyrazoloä4,3-düpyrimidine
UA82292C2 (uk)	2004-04-14	2008-03-25	Пфайзер Продактс Инк.	Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти)
MXPA06011891A (es)	2004-04-20	2007-04-24	Pfizer	Metodo para tratar el dolor neuropatico.
EP1740211A2 (en)	2004-04-20	2007-01-10	Pfizer Products Incorporated	Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
WO2005102390A2 (en)	2004-04-22	2005-11-03	Pfizer Japan, Inc.	Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
BRPI0510453A (pt)	2004-04-30	2007-10-30	Warner Lambert Co	composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7737163B2 (en)	2004-06-15	2010-06-15	Pfizer Inc.	Benzimidazolone carboxylic acid derivatives
WO2005123718A2 (en)	2004-06-15	2005-12-29	Pfizer Japan Inc.	Benzimidazolone carboxylic acid derivatives
MXPA06014228A (es)	2004-06-21	2007-02-14	Warner Lambert Co	Preparacion de pregabalina y compuestos relacionados.
WO2006003500A1 (en)	2004-06-29	2006-01-12	Pfizer Products Inc.	Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
US20060003344A1 (en)	2004-06-30	2006-01-05	Pfizer Inc.	Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
WO2006008640A1 (en)	2004-07-15	2006-01-26	Pharmacia & Upjohn Company Llc	Non-aqueous suspension containing a drug having an unpleasant taste
AU2005266090A1 (en)	2004-07-23	2006-02-02	Pfizer Inc.	Pyridine derivatives
GB0419849D0 (en)	2004-09-07	2004-10-13	Pfizer Ltd	Pharmaceutical combination
MX2007005290A (es)	2004-11-02	2007-07-09	Pfizer	Derivados de sulfonilbencimidazol.
CN101087771A (zh)	2004-11-10	2007-12-12	辉瑞大药厂	经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
US7122683B2 (en)	2004-11-23	2006-10-17	Pfizer Inc.	Amides useful as monoamine re-uptake inhibitors
ATE460415T1 (de)	2004-11-29	2010-03-15	Warner Lambert Co	Therapeutische pyrazoloä3,4-büpyridine und - indazole
AP2007004067A0 (en)	2005-02-22	2007-08-31	Pfizer	Oxyindole derivatives as 5HT4 receptor agonists
WO2006092692A1 (en)	2005-03-01	2006-09-08	Pfizer Limited	Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
ES2331153T3 (es)	2005-03-10	2009-12-22	Pfizer Inc.	Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
JP4521463B2 (ja)	2005-03-17	2010-08-11	ファイザー株式会社	疼痛の治療に有用なｎ−（ｎ−スルホニルアミノメチル）シクロプロパンカルボキサミド誘導体
WO2006111856A1 (en)	2005-04-20	2006-10-26	Pfizer Limited	Pyrazole derivatives as progesterone receptor antagonists
JP4173909B1 (ja)	2005-04-28	2008-10-29	ファイザー・リミテッド	アミノ酸誘導体
AU2006248645A1 (en)	2005-05-20	2006-11-23	Pfizer Limited	Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-delta-ligands
CA2610354C (en)	2005-05-31	2011-03-29	Pfizer Inc.	Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
NL2000281C2 (nl)	2005-11-02	2007-08-07	Pfizer Prod Inc	Vaste farmaceutische samenstellingen die pregabaline bevatten.
NL2000284C2 (nl)	2005-11-04	2007-09-28	Pfizer Ltd	Pyrazine-derivaten.
JP4234786B1 (ja)	2005-11-08	2009-03-04	ファイザー・リミテッド	ピラゾール誘導体およびその医学的使用
BRPI0619126A2 (pt)	2005-12-02	2011-09-13	Pfizer Ltd	derivados espirocìclicos, composição farmacêutica e usos dos mesmos
CA2530904C (en)	2005-12-20	2013-10-08	John Marino	Pharmaceutical agents for the treatment of pain associated with spinal cord injury
CN101420947A (zh)	2006-03-06	2009-04-29	辉瑞产品公司	用于非恢复性睡眠的α-2-δ配体
GB0700786D0 (en)	2007-01-15	2007-02-21	Pfizer Ltd	Morpholine dopamine agonists for the treatment of pain
AU2008211613B2 (en)	2007-02-02	2013-05-23	Pfizer Products Inc.	Tricyclic compounds and their use as glucocorticoid receptor modulators
WO2008132589A1 (en)	2007-05-01	2008-11-06	Pfizer Limited	Combinations comprising pregabalin

1997
- 1997-07-16 IL IL12699997A patent/IL126999A/en not_active IP Right Cessation
- 1997-07-16 AU AU36024/97A patent/AU714980B2/en not_active Expired
- 1997-07-16 US US11/983,750 patent/USRE41920E1/en not_active Expired - Lifetime
- 1997-07-16 BR BR9710536A patent/BR9710536A/pt not_active Application Discontinuation
- 1997-07-16 SI SI9730545T patent/SI0934061T1/xx unknown
- 1997-07-16 AT AT97932617T patent/ATE241351T1/de active
- 1997-07-16 US US09/043,358 patent/US6001876A/en not_active Expired - Lifetime
- 1997-07-16 WO PCT/US1997/012390 patent/WO1998003167A1/en not_active Ceased
- 1997-07-16 KR KR10-1999-7000577A patent/KR100491282B1/ko not_active Expired - Lifetime
- 1997-07-16 CN CN97196041A patent/CN1094757C/zh not_active Expired - Lifetime
- 1997-07-16 PT PT97932617T patent/PT934061E/pt unknown
- 1997-07-16 DK DK97932617.0T patent/DK0934061T6/en active
- 1997-07-16 NZ NZ332762A patent/NZ332762A/xx not_active IP Right Cessation
- 1997-07-16 EP EP97932617.0A patent/EP0934061B3/en not_active Expired - Lifetime
- 1997-07-16 ES ES97932617.0T patent/ES2200184T7/es active Active
- 1997-07-16 DE DE1997622426 patent/DE69722426T3/de not_active Expired - Lifetime
- 1997-07-16 PL PL97331325A patent/PL189872B1/pl unknown
- 1997-07-16 JP JP50706298A patent/JP3693258B2/ja not_active Expired - Lifetime
- 1997-07-16 CA CA002255652A patent/CA2255652C/en not_active Expired - Lifetime
- 1997-07-16 HU HU9904361A patent/HU228426B1/hu active Protection Beyond IP Right Term
- 1997-07-17 HR HR60/022,337A patent/HRP970387A2/hr not_active Application Discontinuation
- 1997-07-23 ZA ZA9706562A patent/ZA976562B/xx unknown
1999
- 1999-01-22 NO NO19990279A patent/NO325822B1/no not_active IP Right Cessation
- 1999-01-22 CU CU1999008A patent/CU22850A3/es unknown
2008
- 2008-12-04 NO NO2008018C patent/NO2008018I2/no unknown
2013
- 2013-08-27 HU HUS1300046C patent/HUS1300046I1/hu unknown

Also Published As

Publication number	Publication date
EP0934061A1 (en)	1999-08-11
DK0934061T3 (da)	2003-09-22
NO990279L (no)	1999-01-22
CN1094757C (zh)	2002-11-27
HUP9904361A3 (en)	2000-11-28
NZ332762A (en)	2000-09-29
DE69722426D1 (de)	2003-07-03
ES2200184T9 (es)	2015-03-20
BR9710536A (pt)	1999-08-17
AU3602497A (en)	1998-02-10
WO1998003167A1 (en)	1998-01-29
NO990279D0 (no)	1999-01-22
ATE241351T1 (de)	2003-06-15
CU22850A3 (es)	2003-04-28
DE69722426T3 (de)	2015-05-07
ES2200184T3 (es)	2004-03-01
EP0934061B3 (en)	2015-01-21
NO2008018I1 (no)	2008-12-15
CA2255652C (en)	2004-07-13
DK0934061T6 (en)	2015-01-26
SI0934061T1 (en)	2003-10-31
HRP970387A2 (en)	1998-10-31
IL126999A0 (en)	1999-09-22
JP3693258B2 (ja)	2005-09-07
US6001876A (en)	1999-12-14
IL126999A (en)	2002-03-10
CN1223574A (zh)	1999-07-21
CA2255652A1 (en)	1998-01-29
HUS1300046I1 (hu)	2016-08-29
EP0934061B1 (en)	2003-05-28
DE69722426T2 (de)	2004-04-08
USRE41920E1 (en)	2010-11-09
ES2200184T7 (es)	2015-02-10
KR100491282B1 (ko)	2005-05-24
ZA976562B (en)	1998-02-03
HUP9904361A2 (hu)	2000-05-28
HU228426B1 (hu)	2013-03-28
JP2000515149A (ja)	2000-11-14
NO325822B1 (no)	2008-07-21
KR20000068015A (ko)	2000-11-25
NO2008018I2 (no)	2010-06-28
PL189872B1 (pl)	2005-10-31
HK1021134A1 (en)	2000-06-02
PT934061E (pt)	2003-10-31
PL331325A1 (en)	1999-07-05

Legal Events

Date	Code	Title	Description
2000-05-18	FGA	Letters patent sealed or granted (standard patent)

Publication	Publication Date	Title
AU714980B2 (en)	2000-01-13	Isobutylgaba and its derivatives for the treatment of pain
CA2255652E (en)	2004-07-13	Isobutylgaba and its derivatives for the treatment of pain
CA2430470C (en)	2008-11-04	Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
AU2002257680A1 (en)	2003-03-27	Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
JP2018021023A (ja)	2018-02-08	（ｓ）２−ｎ（３−ｏ−（プロパン２−オール）−１−プロピル−４−ヒドロキシベンゼン）−３−フェニルプロピルアミドの単離された立体異性体型
EP3818981A1 (en)	2021-05-12	Synergic pharmaceutical composition of the active enantiomer (s)-ketorolac and gabapentin for the treatment of neuropathic pain
US20080139651A1 (en)	2008-06-12	Compounds useful for treating neurological disorders
HK1021134B (en)	2003-07-18	Isobutylgaba and its derivatives for the treatment of pain
HK1143088A (en)	2010-12-24	Novel use of a peptide class of compounds for treating diabetic neuropathic pain